Multiple sclerosis. Demyelinating diseases of the central nervous system
Conditions
Interventions
Intervention 1: Intervention group: Bromelin capsules will use 200 milligrams of yellow color, equivalent to placebo capsules and manufactured by Iran's Parmon Amin Company 3 times a day, and 10 days
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: All patients with MS who have Expanded Disability Status Scale (EDSS) equal or less than 4. Patients with MS aged 18 to 50 years old Informed consent Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
Exclusion criteria
Exclusion criteria: Use of other complementary and alternative methods during the study Sleeping and sedative medications, antidepressants and analgesics during the study smoking Major depressive disorder History of epilepsy, cardio-pulmonary and metabolic diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cortisol levels. Timepoint: At the beginning of the study before the intervention, after 12 hours of fasting at 8 o'clock in the morning, as well as at the end of the eleventh day intervention. Method of measurement: blood test.;Stress. Timepoint: Measurement at the beginning of the study (before intervention) and 11 days after intervention. Method of measurement: Depression Anxiety Stress Scale 21 (DASS-21).;Depression. Timepoint: Measurement at the beginning of the study (before intervention) and 11 days after intervention. Method of measurement: Depression Anxiety Stress Scale 21 (DASS-21).;Anxiety. Timepoint: Measurement at the beginning of the study (before intervention) and 11 days after intervention. Method of measurement: Depression Anxiety Stress Scale 21 (DASS-21). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFahimeh Davodabady
Arak University of Medical Sciences
Outcome results
None listed